DOI: 10.3724/SP.J.1105.2014.13288

Acta Polymerica Sinica (高分子学报) 2014/014:2 PP.263-269

Studies on Dextran Gadolinium Complex Containing Sulfadiazine Groups

Sulfadiazine-containing dextran ligand (SD-Dextran-DTPA) was synthesized by the incorporation of diethylenetriaminepentaacetic acid (DTPA) and sulfadiazine (SD) as a tumor-targeting group into dextran. This ligand was further reacted with gadolinium chloride to produce tumor-targeting macromolecule gadolinium complex (SD-Dextran-DTPA-Gd). Experimental data of 1H-NMR, IR, UV, average particle sizes and zeta potential evidenced the formation of the dextran ligand and gadolinium complex. In vitro properties including the relaxivity, cell uptake assay and magnetic resonance imaging were also evaluated. In the aqueous solutions, the average diameter of the dextran ligand SD-Dextran-DTPA and complex SD-Dextran-DTPA-Gd increased when the concentration of their solutions decreased. Compared with Gd-DTPA, this tumor-targeting dextran gadolinium complex SD-Dextran-DTPA-Gd possessed obviously higher relaxation effectiveness due to a slowly tumbling system and an increase in rotational correlation time. The cell uptake assay indicated that SD-Dextran-DTPA-Gd had a high affinity to the H460, MDA-MB-231 and T40D tumor cells and can be taken up selectively by these tumor cells. Magnetic resonance imaging (MRI) tests showed that SD-Dextran-DTPA-Gd possessed the relaxation effectiveness higher than that of Gd-DTPA and can enhance the contrast of MR images of the tumor cells. Moreover, the T1 signal intensities of the MDA-MB-231 cell suspensions were obviously higher than those of the H460 and T40D cell suspensions. Therefore SD-Dextran-DTPA-Gd has shown the potential as a tumor-targeting contrast agent in MRI.

Key words:Magnetic resonance imaging, Contrast agent, Tumor-targeting, Dextran, Sulfadiazine, Diethylenetriaminepentaacetic acid

ReleaseDate:2014-07-21 17:05:31

1 Lauffer R B.Chem Rev,1987,87:901~907

2 Caravan P,Ellison J J,Mcmurry T J,Lauffer R B.Chem Rev,1999,99:2293~2352

3 Weinmann H J,Brash R C,Press W R,Wesby G E.Am J Radiology,1984,142:619~624

4 Laurent S.Eur J Inorg Chem,2007:2061~2067

5 Villaraza A J L,Bumb A,Brechbiel M W.Chem Rev,2010,110:2921~2959

6 Driksen A,Langereis S,de Waal B F M,van Genderen M H P,Meijer E W,de Lussanet Q G,Hackeng T M.Organic Letters,2004,6(26):4857~4860

7 Comblin V,Gilsoul D,Hermann M,Humblet V,Jacques V.Coord Chem Rev,1999,185:451~470

8 Yan G P,Robinsonand L,Hogg P.Radiography,2007,13:e5~e19

9 Yan G P,Ai C W,Zong R F,Liu F.Chinese Sci Bull,2010,55(27-28):3085~3093

10 Yan G P,Zhuo R X.Chinese Sci Bull,2001,46(15):1233~1237

11 Yan G P,Li Z,Xu W,Zhang Q,Li L,Liu F,Han L,Ge Y X,Guo J F.Int J Pharm,2011,407:119~125

12 Yan G P,Liu M L,Li L Y.Bioconjugate Chem,2005,16:967~971

13 Bartulin J,Przybylski M,Ringsdorf H,Ritter H.Makromol Chem,1974,175:1007~1010

14 Abel G,Connors T A,Ross W C J,Nguyen-Hoang-Nam Hoellinger H,Pichat L.Eur J Cancer,1973,9:49~54

15 Huang J L,Wang H Y,Zhou C L.J Appl Polym Sci,1995,58:8~11

16 Yan G P,Zong R F,Li L,Fu T,Liu F,Yu X H.Pharm Res,2010,27:2743~2754

17 Rinaudo M.Macromol Symp,2007,245-246:549~557

18 Rinaudo M.Polym Int,2008,57(3):397~430

19 Yan G P,Xu W,Yang L,Li L,Liu F,Guo Q Z.Pharm Res,2010,27(9):1884~1892